Skip to main content
Signal8
Launch Terminal

Bambusa Therapeutics, Inc. (BBTX)

Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Bambusa Therapeutics Inc. logo

Bambusa Therapeutics Inc.

NASDAQ:BBTXHealthcare
$14.99
AH$14.21-5.20%vs close
Mkt Cap$745.93M
Float3.53M
O/S49.76M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Bambusa Therapeutics Inc. logoNASDAQ:BBTX$14.99
Phase Distribution
6 lead-sponsored trials·6 active·0 completed
Phase 14
Phase 1/22
Status Overview
Recruiting6

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Phase
  • Phase 1/2
    Recruiting

    A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma

    BBT002, Placebo

    Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    Enrollment
    64
    Start
    Mar 2026
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2028est.
    NCT07436949
  • Phase 1/2
    Recruiting

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

    BBT001, Placebo

    Chronic Spontaneous Urticaria

    Enrollment
    48
    Start
    Jun 2026
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2028est.
    NCT07717905
  • Phase 1
    Recruiting

    A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

    BBT001, Placebo

    Atopic Dermatitis

    Enrollment
    237
    Start
    Feb 2025
    Primary Completion
    Feb 2027est.
    Completion
    Feb 2027est.
    NCT06808477
  • Phase 1
    Recruiting

    A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

    BBT002, Placebo

    Chronic Obstructive Pulmonary Disease

    Enrollment
    286
    Start
    May 2025
    Primary Completion
    Jan 2027est.
    Completion
    Jul 2027est.
    NCT06944925
  • Phase 1
    Recruiting

    A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

    BBT001, Placebo

    Atopic Dermatitis

    Enrollment
    99
    Start
    Aug 2025
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2028est.
    NCT07239947
  • Phase 1
    Recruiting

    A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)

    BBT002, Placebo

    Chronic Obstructive Pulmonary Disease (COPD)

    Enrollment
    68
    Start
    Sep 2025
    Primary Completion
    Dec 2026est.
    Completion
    May 2027est.
    NCT07288554
Search ClinicalTrials.gov for “Bambusa Therapeutics”